GSK plc
linerixibat
cholestatic pruritus in primary biliary cholangitis (PBC)
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for linerixibat in cholestatic pruritus in primary biliary cholangitis (PBC) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“Marketing applications for linerixibat are currently under regulatory review in the US, EU, UK, China and Canada, based on positive data from the GLISTEN phase III trial.”